http://www.lilly.com/

Christopher A. Slapak, MD, Distinguished Lilly Scholar Cancer Research and Clinical Investigation  Lilly Research Laboratories  /Eli Lilly and Company ; Clinical Associate Professor of Medicine  Indiana University School of Medicine

Presentation on:

Eli Lilly Oncology Pipeline Overview

---

http://www.novelos.com

Christopher Pazoles, PhD - Vice President, Research and Development
Kristin Schuhwerk - Vice President of Clinical Development, Operations

Programs Presented:

• NOV-002, redox-regulating oxidized glutathione-mimetic.

---

http://www.jnj.com/connect/

Bill Hait , MD , PhD ; Senior Vice President,  Worldwide Head of Oncology/ Hematology R&
Chris Takimoto , MD, PhD; Senior Director,  Translational Medicine 
Craig Tendler, MD, Vice President, Medical Affairs, Oncology and Nephrology, Ortho Biotech
Catherine Oyler, MBA, Senior Director, Emerging Technologies, Corporate Office of Science and Technology

Presentation on:

• CNTO 328 - anti-interleukin(IL)-6 monoclonal antibody
• CNTO 888 - Anti-CLL2 human monoclonal antibody
• hdm2 Inhibitor Program
• Overview over JNJ pipeline

---

<//span>

http://www.arraybiopharma.com

James Winkler, PhD - Vice President, Discovery and Translational Biology
Duncan Walker, PhD - Senior Director, Translational Biology
Laura Maloney - Senior Clinical Program Manager 

Presentation on:

• ARRY-543 – panErB inhibitor
• ARR-Y520 – KSP inhibitor
• ARRY-380 – ErB2 inhibitor
• ARRy-614 – p38/ tie-2 inhibitor

---

http://www.emdserono.com/en/index.html

Jens Oliver Funk, MD, Senior Vice President, Merck Serono Research /Global Head of TA Oncology
Frank T. Weber, MD, PhD; Senior Vice President, Merck Serono Research; Head of Exploratory Medicine
Oscar Kashala, MD, PhD, DSc; Senior Medical Director, Development; Head US Oncology Development

Presentation on:

• Erbitux
• Cilengitide – Cyclic RGD peptide integrin inhibitor
• DI17E6 – Anti-Integrin Antibody
• Stimuvax – Therapeutic MUC1-based cancer vaccine
• Survivac – Therapeutic survivin-based cancer vaccine
• Selectikine – NHS-IL2-LT immunocytokine
• Aurora Multikinase Inhibitor (AS703569)
• MEK Inhibitor (AS703026)

---

 

http://www.curis.com/index.php

Bill Munger - Executive Director Technology and Program Management
Cheng Lai, PhD - Director, Molecular and Cellular Biology
Xu Tao, PhD - Associate Director, Molecular and Cellular Biology
Khanh Ly, MSc, Esq - Director, Coproate Development and Strategic Planning

Presentation on:

• GCD-0449, a hedgehog antagonist (Collaboration with Genentech)
• CUDC-305 (Hsp90 inhibitor), and
• multi-targeted small molecule inhibitors (HDAC combinations).

---

http://www.biparsciences.com

Charles Bradley, PhD - Vice President Clinical Development 

Presentation on:

• PARP inhibitor program – BSI 201 and other PARP inhibitor candidates

---

http://www.imclone.com

Eric Rowinsky, MD - Chief Medical Officer and Executive Vice President

Presentation on:

"The ImClone Pipeline of Human IgG1 Antibodies - Overview and Potential Collaborations"

---

http://www.cephalononcology.com

Joseph Leveque, MD - Senior Group Director, Medical and Scientific Affairs
Bruce Ruggeri, PhD - Senior Director, Oncology Research Drug Discovery
Peter Brown, DPhil - Vice President, Translational Medicine
Melanie Olesky, PhD - Medical Science Liaison

Presentation on:

• TRISENOX®  (arsenic trioxide) for  Injection   Acute   Myeloid Leukemia- Approved  
• TREANDA® (bendamustine  hydrochloride) for Injection Chronic  lymphocytic leukemia (CLL) - Approved  
• CEP-701 (lestaurtinib) - Acute myelogenous leukemia (FLT3) - Phase  III
• CEP-701   (lestaurtinib) - Myeloproliferative disorders  (JAK2) - Phase  II  
• CEP-11981 (VEGF-R/TIE2 Kinase inhibitor) – Solid Tumors - Phase    I
• CEP-18770 (proteasome inhibitor) - Multiple Myeloma - Phase  1
• CEP-18050 AnaplasticLarge Cell Lymphoma - Preclinical

---

http://:www.gsk.com

Peter Ho, MD, PhD - Senior President, Oncology CEDD
Babara Weber, MD - Vice President, Discovery and Translational Medicine Oncology

Presentation on:

• AKT Inhibitor Development Program
• CENPE
• PLK (Anti-Mitotics)
• MEK Inhibitor Program
• PI3K Inhibitor Program
• Eleclomol (with Synta Pharmaceuticals)
• GSK Go/No-Go Decisions

---

http://www.abbott.com

Saul Rosenberg, PhD - Senior Director, Discovery
Gary Gordon, MD, PhD - Divisional Vice President, Pharmaceutical Development

Presentation on:

• ABT-869 - small molecule RTKI of VEGF/PDGF
• ABT-263 - small molecule Bcl-2 Family Inhibitor
• ABT-888 - small molecule PARP Inhibitor

---

http://www.progenra.com/

Ben Nicholson, PhD – Associate Director

Presentation on:

• Ubiquitin and ubiquitin-like proteins

---

http://www.syntapharma.com/

Jim Barsoum, PhD – SVP, Research
Eric Jacobson, MD – Senior Vice President, CMO

Presentation on:

• Elesclomol (STA-4783) (Increases Reactive Oxygen Species)
• STA-9090 (Hsp90 Inhibitor)
• STAF-584 (Vascular Discrupting Agent)

---

http://www.methylgene.com

Robert Martell, MD – VicePresident and Chief Medical Officer

Presentation on:

• MGCD0103 (HDAC Inhibitor)
• MGCD 265 (Met Inhibitor)

---

http://www.arqule.com

Dennis France - Vice President, Molecular Oncology
Tom Chan, MD - Senior VP, Discovery and Pre-Clinical Development
Mark Ashwell, PhD - VP, Drug Discovery Chemistry
Martin Redmon, PhD - VP, Pharmaceutical Development

Presentation on:

• ARQ197 - c-met Inhibitor (Kyowa Hakko)
• ARQ350RP - b-raf Kinase Inhibitor
• ARQ300RP - Eg5 Inhibitor
• ARQ171 - E2F1 Pathway Activator (Roche)
• ArQule's Approach to Drug Discovery and Development